EGFR and lung carcinoma: A post-hoc analysis of data from 32 patients pooled from LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 trials revealed clinical activity of afatinib against rare EGFR mutant (G719X, S786I, L861Q) lung cancers [9].